Lactobacillus Rhamnosus GG

Phase 1

MMedstar Health Research Institute

Lactobacillus Rhamnosus GG is one of 50 therapeutic programs targeting Spinal Cord Injury. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Spinal Cord InjuryNot yet recruiting

Spinal Cord InjuryPhase 1

Not yet recruiting

Competition

Competitive Landscape

62 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

5 2

Levitra

Bayer

Approved

1 3

Elavil

AstraZeneca

Approved

1 4

Keppra

UCB

Approved

1 5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 6

Calciferol

Lioresal

Prolia

2 9

Botox

GGalderma R&D

Approved

1 10

Xarelto

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Spinal Cord Injury

NCT07643974

Clinical

Trials by Indication[1]

Spinal Cord Injury1 trial

Effect of Dose Timing of Coupled Intravesical Gentamicin and Lactobacillus Rhamnosus LGG on Success and Length of Colonization in Men and Women With SCI/D and NLUTD

Not yet recruiting·MMedstar Health Research Institute·Phase 1·NCT07643974·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactobacillus Rhamnosus GG. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lactobacillus Rhamnosus GG. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Medstar Health Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: MMedstar Health Research Institute

Lactobacillus Rhamnosus GG

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News